Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Picankibart in Active Psoriatic Arthritis
NCT07295509Phase 3Recruiting
- Sponsor
- Innovent Biologics
- Start
- Dec 2025
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of picankibart in psoriatic arthritis (PsA), sponsored by Innovent Biologics. Started Dec 2025; status: recruiting.
02
Drugs
picankibart
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT07295509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07295509.